POST-AAIC 2022 is coming again, and the most cutting-edge progress in Alzheimer's disease research is waiting for you to check~

*For medical professional reading reference only

• Pathologically, a case report showed that AD patients treated with lencanetumab had less diffuse amyloid deposition in the brain, a lower burden of neuritic plaques, and Aβ plaques also appeared "moth-eaten", which is less Plaques were less dense and more sparse in texture in lencanetumab-treated patients, suggesting that lencanetumab may clear diffuse and neuropathic brain amyloid deposits ^[3]
  
  
  
  Although the dawn is ahead, the development of new drugs for AD still has a long way to go.
  
  
  
  
  • The cholinesterase inhibitor donepezil can delay the progression of AD-derived MCI to AD in the early stage, but its long-term effect still needs more large-sample clinical trials to study (Class IIa recommendation, Level B evidence);
    
    SIB: Severe Impairment Battery, Severe Impairment Scale
    
    2
    
    
    
    As a grand gathering of global AD scholars, it is essential to explore the pathophysiological mechanisms and biomarkers of the disease
    .
    
    Currently, markers such as Aβ, Tau protein, α-synuclein, and TDP-43 have been found to guide the diagnosis and treatment of various neurodegenerative diseases including Alzheimer's disease
    .
    
    At this conference, the Alzheimer's Association issued the following recommendations for the use of AD blood biomarkers ^[7] :
    
    • For AD clinical trials evaluating disease-modifying treatments, such as AD diagnosis by PET or cerebrospinal fluid (CSF), blood-based biomarkers (BBMs) can be used as an initial screening step
      .
      
    • BBM may be used as an exploratory outcome or to inform decision-making in adaptively designed trials, but should not be used as the primary endpoint
      .
      
      
    • In the memory clinic, BBM should only be used in symptomatic patients, and the diagnosis should be confirmed by CSF or PET
      .
      
      
    • The use of BBMs in primary therapy is currently not recommended
      .
      
      
    Regarding AD biomarkers, the most debated question in recent years is: Can people with normal cognition but positive AD biomarkers be able to diagnose AD? The International Working Group on Alzheimer's Disease (IWG) and the National Institute on Aging and Alzheimer's Association (NIA-AA) also debated this issue
    .
    
    IWG believes that biomarkers cannot fully predict AD, and the population with positive biomarkers may remain cognitively normal for life, and this part of the population should be defined as AD risk people; however, NIA-AA believes that the course of AD is continuous and is It starts with pathological changes in the brain of asymptomatic people, and this change will eventually manifest clinical symptoms, which is preclinical AD
    .
    
    However, in current clinical practice, biomarker testing is still not recommended for asymptomatic populations; however, the research framework of biomarkers and methods for predicting whether individuals will develop AD need to be continuously updated
    .
    
    

     

    Beyond diagnostics, researchers are also exploring whether biomarkers could be therapeutic targets
    .
    
    Tau oligomers are intermediate forms of Tau that appear before the formation of neurofibrillary tangles.
    Because of their small molecular weight and fast formation speed, they can spread rapidly between neurons and induce abnormal intracellular aggregation of Tau
    .
    
    Sònia Sirisi Dolcet et al.
    found that Tau oligomers were found in presynaptic and postsynaptic terminals in different regions of the brain, with a higher proportion in presynaptic terminals; Tau was also found in areas without a large number of fibrillar Tau oligomers
    .
    
    These results suggest that Tau oligomers are an intermediate form prior to neurofibrillary tangles formation in different brain regions, and early blocking of its formation may prevent its spread across synapses ^[8]
    .
    
    
    3
    The new crown pandemic, digital technology empowers AD management
    The ravages of the new crown epidemic around the world have changed people's lives in many ways; and in today's digital age, the Internet has also brought infinite possibilities for health management and disease diagnosis and treatment
    .
    
    Swedish researchers conducted a survey to investigate changes in lifestyle and psychosocial factors related to AD and dementia in older Swedish adults during the COVID-19 pandemic
    .
    
    The results showed that the elderly had more unhealthy food intake, less physical activity, less contact with relatives, friends and others, more hopelessness and loneliness about the future, and more sleep problems
    .
    
    The researchers believe that during the epidemic, doctors need to understand and pay attention to these changes and take targeted interventions; digital technology tools can be considered to prevent AD and dementia ^[9]
    .
    
    When it comes to digital technology tools, many researchers are keenly aware of their potential
    .
    
    For example, researchers at Harvard Medical School explored the possibility of remote digital devices in the early diagnosis of AD
    .
    
    In the study, participants completed three "Boston Remote Assessment of Neurocognitive Health" (BRANCH) tasks via a remote device each day for 7 days and established a multi-day learning curve (MDLC)
    .
    
    The results showed that the curve could represent the preclinical cognitive changes of the elderly, and the decrease of the curve was statistically correlated with the increase of the neural markers Aβ and Tau protein
    .
    
    The researchers believe that remote early detection may help identify the preclinical stage of AD and seize the window of hope for preventing cognitive decline ^[10]
    .
    
    

     

    The above are just some of the selected content of this AAIC conference.
    Do you feel that you are still not satisfied after reading the above content?For two consecutive years from 2020 to 2021, Eisai China successfully held two POST-AAIC sessions
    .
    
    At previous conferences, domestic experts in the field of AD gathered together to interpret the most cutting-edge developments of AAIC, share and discuss the latest research results and clinical strategies, and find further directions for clinical decision-making and scientific research in AD.
    The gluttonous academic feast brought up many practical clinical problems and new clinical ideas
    .
    
    The continuous accumulation of these contents not only allows us to see the gratifying achievements in the research and development of new Aβ drugs, but also allows us to gradually see new hope and new dawn for the treatment of AD patients
    .
    
    In 2022, when the AAIC reverberates around, the annual "Eisai China POST-AAIC" conference will once again be ready to go.
    Academic Dynamics!
    Wonderful photos of POST-AAIC in 2020
    Highlights from past conferences

    View the POST-AAIC schedule

    ↓↓↓

    Swipe left and right to view all

    References: [1] Yamauchi E, et al.
    AAIC 2022-Poster.
    Analysis of interaction characteristics between amyloid β and Lecanemab by HDX-MS.
    [2] Monfared AAT, et al.
    AAIC 2022-Poster.
    Lifetime Clinical Benefits of Lecanemab in Early Alzheimer's Disease Using Simulation Modeling.
    [3] Lawrence S, et al.
    AAIC 2022-Poster.
    Autopsy Findings in an Individual with Alzheimer's Disease who Received Long-Term Treatment with Lecanemab (BAN2401).
    [4] Landry l, et al.
    AAIC 2022-Poster.
    Lecanemab(Ban2401) Infusion Reactions And Immunogenicity: Results From Randomized Phase 2 Study And An Open-Label Extension.
    [5] Rawal S, et al.
    AAIC 2022-Poster.
    ABSOLUTE BIOAVAILABILITY OF A SINGLE, FIXED SUBCUTANEOUS DOSE OF LECANEMAB IN HEALTHY SUBJECTS.
    

    [6] Hayato S, et al.
    AAIC 2022-Poster.
    SUBCUTANEOUS DOSE SELECTION OF LECANEMABFOR TREAT- MENT OF SUBJECTS WITH EARLY ALZHEIMER'S DISEASE.
    

    [7] The Alzheimer's Association Appropriate Use Recommendations for Blood Biomarkers in Alzheimer' s Disease.
    Data Presentations at Alzheimer' s Association International Conference 2022.
    Retrieved July 31, 2022, from https://onlinexperiences.
    com/scripts/Server.
    nxp

    [8] Synaptic oligomeric Tau is an early event in tau-affected brain regions in Alzheimer' s disease.
    Data Presentations at Alzheimer' s Association International Conference 2022.
    Retrieved July 31,2022, from https://onlinexperiences.
    com/scripts/Server.
    nxp

    [9] Changes in modifiable risk factors for Alzheimer's disease and dementia during the COVID-19 pan-demic in Swedish older adults: a population-based digital survey.
    Data Presentations at Alzheimer's Association International Conference 2022.
    Retrieved July 31, 2022

    [10] Preclinical detection of cognitive decline using digital technologies-The EdoN Initiative.
    Data Presentations at Alzheimer's Association International Conference 2022.
    Retrieved July 31,2022, from https://onlinexperiences.
    com/scripts/Server.
    nxp

    *This article is only used to provide scientific information to medical and health professionals, and does not represent the platform's viewpoint submission/reprint/business cooperation: yxjsjbx@yxj.
    org.
    cn